InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,303.20
(
0.46%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.42
(
1.12%
)
Bitcoin
61,577.87
(
1.26%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

BTH

Send PM Follow Ignore
Followers 16
Posts 4145
Boards Moderated 1
Alias Born 06/11/2010

BTH

Re: Checkpoint post# 161292

Friday, 05/17/2013 9:35:17 PM

Friday, May 17, 2013 9:35:17 PM

Post# of 252412
I am entirely in your camp, Checkpoint, regarding PD-1 potential and getting value from the Yervoy franchise. Complete regression is complete regression any way you cut it, and durability. There have been complete responses in Stage 4 NSCLC in the combination studies with only a few cycles of Yervoy combined with PD1. Pretty unprecedented. This is leaps and bounds beyond Avastin.

See this article today from a patient:

http://www.salon.com/2013/05/17/my_truly_remarkable_cancer_breakthrough/

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up